CG Oncology Stock Quote CGON - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

28.95

Bid

27.96

Ask

30.24

Volume

762,412

28.20 Day's Range 30.245

28.20 52 Week Range 50.23

Market Cap

1.377B

Previous Close

30.02

Open

30.01

Last Trade

1342

28.95

(formt)

Last Trade Time

Financial Volume

$ 22,000,867

VWAP

28.8569

Average Volume (3m)

610,337

Shares Outstanding

48,330,000

Dividend Yield

PE Ratio

-20.32

Earnings Per Share (EPS)

-1.4

Revenue

204k

Net Profit

-67.8M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

cgoncology.com

Headquarters

Dover, Delaware, USA

Founded

1970

CG Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGON. The last closing price for CG Oncology was $30.02. Over the last year, CG Oncology shares have traded in a share price range of $ 28.20 to $ 50.23.

CG Oncology currently has 48,330,000 shares outstanding. The market capitalization of CG Oncology is $1.38 billion. CG Oncology has a price to earnings ratio (PE ratio) of -20.32.

Form 8-K - Current report

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)First...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call...

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

- PIVOT-006 Phase 3 open-label trial of adjuvant cretostimogene is CG Oncology’s earliest disease stage clinical trial for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) - - Primary...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-11.3	-28.0745341615	40.25	46.99	28.2	1223552	34.52953683	CS
4	-10.83	-27.2247360483	39.78	46.99	28.2	617537	36.66482415	CS
12	-19.31	-40.0124326564	48.26	50.23	28.2	610337	38.87599892	CS
26	-0.05	-0.172413793103	29	50.23	28.2	692159	38.6838984	CS
52	-0.05	-0.172413793103	29	50.23	28.2	692159	38.6838984	CS
156	-0.05	-0.172413793103	29	50.23	28.2	692159	38.6838984	CS
260	-0.05	-0.172413793103	29	50.23	28.2	692159	38.6838984	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
LIDRAEye Inc	$ 2.5406 (111.72%)	158.99M
NVAXNovavax Inc	$ 8.90 (98.66%)	170.86M
LGHLWLion Group Holding Ltd	$ 0.0059 (63.89%)	372.41k
ITOSiTeos Therapeutics Inc	$ 17.44 (43.07%)	5.26M
SRTSSensus Healthcare Inc	$ 5.3194 (39.62%)	19.74M
MGNXMacroGenics Inc	$ 3.31 (-77.44%)	35.15M
EVLVEvolv Technologies Holdings Inc	$ 2.355 (-38.67%)	14.74M
GWAVGreenwave Technology Solutions Inc	$ 0.0435 (-37.77%)	91.14M
SGDSafe and Green Development Corporation	$ 0.576 (-32.05%)	6.54M
NBSTWNewbury Street Acquisition Corporation	$ 0.0695 (-30.50%)	10.52k
NVAXNovavax Inc	$ 8.90 (98.66%)	170.86M
LIDRAEye Inc	$ 2.5406 (111.72%)	158.99M
NKLANikola Corporation	$ 0.537 (-6.77%)	113.59M
FFIEFaraday Future Intelligent Electric Inc	$ 0.0458 (12.81%)	101.35M
SQQQProShares UltraPro Short QQQ	$ 10.61 (-0.66%)	99.85M